Welcome to our dedicated page for Kane Biotech news (Ticker: KNBIF), a resource for investors and traders seeking the latest updates and insights on Kane Biotech stock.
Kane Biotech Inc. (KNBIF, TSX-V: KNE) generates news primarily around its wound care biotechnology activities, especially the development and clinical use of its revyve ae Antimicrobial Wound Gel and Wound Gel Spray. Company updates frequently highlight how these products are designed to disrupt biofilms and address wound bacteria, which Kane Biotech identifies as key contributors to antibiotic resistance and complex wound outcomes.
News releases often cover regulatory milestones, such as FDA 510(k) clearances for revyve Antimicrobial Wound Gel and Spray, Health Canada approvals for the gel and spray, and the submission of a 510(k) application for revyve Antimicrobial Wound Cleanser. Investors and clinicians can also follow announcements about clinical and pre-clinical data, including case series in diabetic foot ulcers, burn wounds, chronic radiation-induced ulcers, venous leg ulcers, and other challenging wound types.
Kane Biotech regularly reports participation in wound care and burn conferences, where it presents data on healing trajectories, infection control, and biofilm management using revyve products. These events include meetings such as the Symposium on Advanced Wound Care, Diabetic Foot Conference, Southern Region Burn Conference, Innovations in Wound Healing, and other specialized gatherings.
In addition, the company issues news on financing and corporate developments, including private placement offerings, financial results, board and committee changes, and interactions with funding partners. For readers tracking KNBIF, this news page provides a centralized view of Kane Biotech’s scientific, regulatory, clinical, and corporate announcements related to its wound care biotechnology focus.
Kane Biotech Inc. will release its Q1 2021 financial results on May 27, 2021. A conference call is scheduled for 4:30 p.m. ET to discuss the results and business developments. The company specializes in technologies to prevent and remove microbial biofilms, holding a portfolio of 53 patents and various trademarks. Kane Biotech is listed on TSX-V under the symbol KNE and on OTCQB under KNBIF. Risks include financial instability, reliance on equity financing, and potential impacts from COVID-19.
Kane Biotech Inc. has announced positive results from a significant consumer trial of its DermaKB™ products, conducted from November 2020 to January 2021. Of over 4,500 participants, 1,402 completed questionnaires, revealing that 82% saw symptom improvement after using Detoxifier and Shampoo, with an average 33% reduction in symptom severity from just a 3 oz. sample. Remarkably, 63% of users preferred DermaKB™ over their previous leading dandruff shampoo. This trial highlights the market need for these products, suggesting strong consumer interest and potential growth for the company.
Kane Biotech Inc. (OTCQB: KNBIF) announced the engagement of Dr. Allan Mandelzys as an advisor to its Board of Directors, with a nomination for board directorship at the upcoming Annual and Special Meeting on May 26, 2021. Dr. Mandelzys brings extensive experience in the biotechnology sector, having held key roles in various companies, including Searchlight Pharma and Matrizyme Pharma. His expertise is expected to enhance Kane's strategic growth, especially in addressing challenges like microbial biofilms and antibiotic resistance.
Kane Biotech Inc. (OTCQB:KNBIF) will release its fourth quarter and full year 2020 financial results on March 25, 2021, after market close. The management team will hold a conference call at 4:30 p.m. ET to discuss these results and business developments. The call can be accessed at 1-877-268-9044 (Canada) or 1-706-679-2995 (International), with replay available at 1-404-537-3406. Kane Biotech specializes in biotechnology focused on microbial biofilm solutions and holds a substantial portfolio of intellectual property.
Kane Biotech Inc. (OTCQB: KNBIF) announced that CEO Marc Edwards will present at the Emerging Growth Virtual Conference on March 17-18, 2021. The event will feature discussions and presentations from various leaders in the Biotech and Healthcare sectors. Edwards expressed excitement about sharing the company's growth story, highlighting successes in commercializing products across three markets and securing government funding. Kane Biotech specializes in technologies that prevent and remove microbial biofilms, holding a robust portfolio of intellectual property.
Kane Biotech Inc. (OTCQB: KNBIF) announced that preliminary analysis of efficacy trials for STEM Animal Health's pet oral care additive has successfully met its primary endpoint. This achievement opens the door for two milestone payments from STEM's licensing partners, contingent on positive clinical efficacy data. STEM's products utilize Kane’s patented Coactiv+™ technology aimed at combating plaque and tartar biofilm in pets. The collaboration between Kane and Animalcare Group focuses on advancing biofilm-related treatments in animals.
Kane Biotech Inc. (OTCQB:KNBIF) announced leadership changes, with Mark Nawacki becoming Chairman of the Board, while Philip Renaud transitions to Vice Chair. Renaud, the outgoing Chairman, emphasized the need for experienced leadership as the company approaches crucial advancements in Wound Care. Nawacki, with a background in pharmaceutical commercialization, expressed gratitude to Renaud and committed to guiding Kane Biotech's growth. The company specializes in technologies that combat microbial biofilms and holds 52 patents, indicating its strong research foundation.
Kane Biotech Inc. announces that Kevin Cole will be the new President and CEO of STEM Animal Health Inc., its subsidiary formed through a joint venture with Animalcare Group PLC. Cole has extensive experience in the pet care industry, previously serving as President of True Leaf Pet. His focus will be on expanding STEM's reach in the $150 billion global pet care market, intent on leveraging the company's innovative biofilm-targeting technology. Additionally, a new Board of Directors has been established to support STEM, with Kane Biotech’s CEO Marc Edwards as Chairman.